AUTHORS
Ibrahim Muhsen, MD, Laurent Garderet2, Mickey Koh, MD, PhD3, Dietger Niederwieser, MD4, Christian Chabannon, MD, PhD5, Nina Worel, MD6, Zaid Abdel Rahman, MD7, Mostafa Saleh, MD8, Raheel Iftikhar9, Marwan Shaheen, MD10, Yoshiko Atsuta11, Pedro Henrique Las Casas, MD PhD12, Cristobal Frutos, MD13, Nada Hamad, MBBS, MSc, BSc14, Hildegard Greinix, MD15, Riad Elfakih16, Yoshihisa Kodera, MD17, Sebastian Galeano, MD18, Mahmoud Aljurf, MD19, Mohammed-Amine Bekadja, MD, PhD20
AFFILIATIONS
1 The University of Alabama at Birmingham, Birmingham, Alabama, United States
2 Centre de Recherche Saint-Antoine, Sorbonne Université-INSERM, Paris, France
3 St. George's Hospital and Medical School, London, United Kingdom
4 University of Leipzig, Leipzig, Germany
5 Institut Paoli-Calmettes, Inserm CBT-1409 & Aix-Marseille Université, Marseille, France
6 Medical University of Vienna, Vienna, Austria
7 King Hussein Cancer Center, Amman, Jordan
8 King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
9 Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
10 King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
11 Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan
12 Centre de Recherche Saint-Antoine, Sorbonne University, Paris, France
13 Instituto de Prevision Social, Asunción, Paraguay
14 St Vincent's Hospital Sydney, Sydney, Australia
15 Medical University of Graz, Graz, Austria
16 King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
17 Aichi Medical University School of Medicine, Nagakute, Japan
18 Hospital Británico, Montevideo, Uruguay
19 King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
20 EHU 1st November, Oran, Algeria
ABSTRACT
Introduction:
Autologous hematopoietic cell transplantation (Auto-HCT) is currently used for the treatment of multiple lymphoproliferative diseases such as multiple myeloma (MM) and lymphoma. Prior to auto-HCT, the vast majority of established transplant programs that operate in high-income countries resort to cryopreservation of collected autologous grafts that are obtained through apheresis. However, cryopreservation requires significant resources and is associated with substantial costs, and thus represents a significant hurdle for programs that are starting their activities, especially when operating in low- to middle-income countries. An alternative for many transplant centers is to use non-cryopreserved autologous hematopoietic cells that are collected shortly before the administration of the high-dose consolidation chemotherapy regimen and stored over a few days at 4 °C in a monitored refrigerator. Such an approach is especially suitable for patients with multiple myeloma who represent the majority of indications for auto-HCT currently, and in whom high-dose consolidation melphalan therapy is administered over a single day.
Methods:
This is a global cross-sectional survey-based study aiming to characterize practices related to the use of non-cryopreserved stem cells in the treatment of multiple myeloma. The survey was distributed to transplant centers across different regions and completed by program directors or their designees.
Results:
Thirty-one transplant centers responded to the survey from 21 different countries across Asia, Africa, and South America. Most centers (n=25, 81%) perform more than 10 auto-HCT for MM. Of these, 7 centers reported performing >40 auto-HCT. Twenty centers (65%) reported performing auto-HCT within 3-6 months of MM diagnosis. Twenty-eight centers (90%) reported having access to plerixafor. Different mobilization strategies are utilized by participating transplant centers, with 58% using G-CSF alone, 32% using G-CSF plus plerixafor, and 10% using G-CSF plus chemotherapy. The target CD34+ count varied by center, with 42% targeting 2×10⁶/kg, 26% targeting 3×10⁶/kg, and 23% targeting 4×10⁶/kg. The rest of the respondents reported other CD34+ cell targets. All centers reported storing stem cells on-site. Regarding non-cryopreserved storage, 26% of centers allow storage up to 24 hours, 35% up to 48 hours, and 26% up to 72 hours. The rest of the participating centers reported longer periods of storage or a disease-specific approach. Around two-thirds of the programs (68%) reported assessing CD34+ cell viability prior to stem cell infusion. Among centers that do not assess viability, cited reasons included shorter storage periods and internal data confirming the lack of need to assess for viability. Prior to auto-HCT, all programs reported using melphalan-based conditioning on day -1 (n=19, 61%) or day -2 (n=12, 39%), with 97% of participating centers reporting using 200 mg/m2 for fit/younger patients and 140 mg/m2 for older/frail patients. All centers reported subsequent administration of G-CSF, which was most commonly initiated on day +5 (n=17, 55%) or day +1 (n=9, 29%). Twenty-seven centers (87%) reported that neutrophil engraftment usually occurs between 10 and 15 days. Additionally, 13 centers reported platelet engraftment between 10 and 15 days, and 17 centers reported it between 16 and 20 days. Seventeen centers (55%) reported that the usual length of hospitalization is 10-15 days, while 39% reported hospitalization exceeding 15 days. Non-relapse mortality was reported to be less than 3% in 80% of the participating centers. The reported cost of non-cryopreserved auto-HCT in MM was less than 15,000 USD in 9 centers (29%) and between 15,000 and 25,000 USD in 11 centers (35%). Only 10 centers reported that the cost exceeded 25,000 USD, with 6 centers (19%) reporting a cost between 25,000 and 50,000 USD, and 4 centers (13%) reporting a cost of more than 50,000 USD.
Conclusion:
In this in-progress global study, we have shown that non-cryopreserved auto-HCT is an increasingly used practice globally, particularly in resource-limited settings. However, we demonstrated heterogeneity in storage duration, viability testing, and associated costs. The study emphasized the favorable outcomes of using this approach. Our findings support the broader utilization of non-cryopreserved auto-HCT; however, they highlight the need for standardization and prospective studies to confirm our results.
DISCLOSURES
Laurent Garderet: Janssen - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)